five

COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media

收藏
DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00000494/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to prevent cases of pneumonia (lung infection) likely caused by bacteria (Streptococcus pneumoniae and Haemophilus influenzae) or cases of otitis media (ear infection) in children under 3 years old.
提供机构:
Vivli
创建时间:
2018-10-27
二维码
社区交流群
二维码
科研交流群
商业服务